Syros Pharmaceuticals (SYRS) Cut to Hold at Zacks Investment Research
Zacks Investment Research downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a buy rating to a hold rating in a research report report published on Wednesday morning.
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
Several other research analysts have also weighed in on the company. BidaskClub raised Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, August 31st. Cann reaffirmed a buy rating and issued a $26.00 target price on shares of Syros Pharmaceuticals in a research report on Tuesday, August 7th. Cowen reaffirmed a buy rating on shares of Syros Pharmaceuticals in a research report on Tuesday, July 17th. HC Wainwright reissued a hold rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, August 8th. Finally, ValuEngine lowered Syros Pharmaceuticals from a hold rating to a sell rating in a report on Monday, June 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Syros Pharmaceuticals has a consensus rating of Hold and an average target price of $19.29.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Friday, August 10th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.07. The firm had revenue of $0.38 million during the quarter, compared to analyst estimates of $1.33 million. As a group, sell-side analysts forecast that Syros Pharmaceuticals will post -1.85 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $119,000. MetLife Investment Advisors LLC acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $134,000. The Manufacturers Life Insurance Company increased its holdings in shares of Syros Pharmaceuticals by 299.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after acquiring an additional 9,691 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $177,000. Finally, Citadel Advisors LLC acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $186,000. 60.70% of the stock is currently owned by institutional investors and hedge funds.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Recommended Story: Average Daily Trade Volume Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.